Organon Articles
TOAST Finds Little Benefit Of Orgaran In Stroke
9 June 1997
Net Income Up 2.4% At Akzo Nobel
5 May 1997
Organon Teknika and Hoffmann-La Roche End Litigation
24 April 1997
UK Industry Code Of Practice In 1996
24 March 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Appointments At Nourypharma And Organon
16 December 1996
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Sanofi Set For Expansion In Sth Africa With OmniMed
18 November 1996
Pharma Flat At Akzo Nobel In 3rd Qtr
11 November 1996
Organon Wins Patent Dispute
14 October 1996
Organon Reorganizes Its Research
7 October 1996
EUROPEAN STOCK COMMENT
7 October 1996
Akzo Nobel And Chinese MoH Sign Health Care Agreement
30 September 1996
ICN Pharmaceuticals Acquires Cappel
30 September 1996
Organon's Remeron Is "Better Than Prozac"
30 September 1996
Organon's Remeron
30 September 1996
Organon/Roche Patent Appeal
23 September 1996
Management Buyout Of PerImmune
9 September 1996
Organon And Signal Alliance; Organon And Chiron Alliance
2 September 1996
Akzo Nobel Sees Earnings Decline
19 August 1996
First Launch Of Organon's Puregon
22 July 1996
New Organon Fertility Drug Unveiled
15 July 1996
UK Industry Code of Practice Review
8 July 1996
First Appro Of Sertindole In UK; Launch Imminent
1 July 1996
Organon's Remeron Cleared In USA
24 June 1996
Organon Teams Up With Pharmacopeia
17 June 1996
EU Patent Case Victory Achieved By Merck & Co And SB
17 June 1996
EMEA Approves Three More Products
3 June 1996
EU Refusal To Block P-Is "Justified"
13 May 1996
Akzo Ups Infar Stake
29 April 1996
CPMP Reaffirms Third Generation Pill Safety
29 April 1996
Atypical Antipsychotic Cuts Schizophrenia Costs
8 April 1996
Risperdal Launched In France
1 April 1996
Organon Licenses Ganirelix From Syntex
19 February 1996
European Stock Markets Review 1995
22 January 1996
EC Commission Acts On Marvelon Price
4 December 1995
Akzo Nobel Results
13 November 1995
Dutch Industry "At A Loss" over Govt Price Plan
6 November 1995
Europe Committee supports desogestrel and gestodene
6 November 1995
Mirtazepine Nears US Approval; 1st Alpha2 Blocker Antidepressant
30 October 1995
Panic Follows UK's Oral Contraceptive Warning
30 October 1995
Anagen Loses Partner For Auraflex
16 October 1995
Organon Teknika / Chiron settlement
16 October 1995
Correction: Organon Teknika and Il Yang Pharmaceutical's BBcell Tab
18 September 1995
Organon Teknika approval for AuraFlex
11 September 1995
Ares-Serono To Expand Stake In Fertility Market
11 September 1995
Anagen/Organon's AuraFlex
4 September 1995
Canada's Cangene Finds Sympathetic Shareholder
21 August 1995
Profit Up 6% At Akzo Nobel
14 August 1995
Gulf States' Pharma Purchasing 1992-94
7 August 1995
Congress Faces Generic Drug Pressure Over GATT
24 July 1995
Ares-Serono R&D Spend 20% Of Sales
10 July 1995
Biomira Sharpens Cancer Management Focus
12 June 1995
Organon and Ares-Serono agree on gonadotrophin
5 June 1995
Organon's Implanon
29 May 1995
Organon/Ares Serono Settle Patent Dispute
29 May 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Japanese Financial Boost For Cangene
29 May 1995
Pharma Sales And Income Up Akzo
15 May 1995
Shortage Of Pergonal And Metrodin In USA
20 March 1995
Murex and Organon Withdraws Appeal
27 February 1995
French Controls On Medical Spending
13 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Russian Contraceptives Venture For Organon
30 January 1995
Fast FDA Approvals Of User-Fee NMEs In 1994
16 January 1995
European Stock Comment
9 January 1995
B-MS' Nefazodone: Launch Soon In USA
9 January 1995
First Launch For Organon's Mirtazapine
2 January 1995
Chiron Victorious In HCV Test Dispute
5 December 1994
UK Hearing On Hepatitis C Sequence Patent Rights
14 November 1994
Mixed Quarterly Results From The USA
14 November 1994
Anagen Slips Further Into Red
31 October 1994
Humegon Approved In USA
19 September 1994
Mixed Results From US Companies In 2nd Qtr
8 August 1994
Chiron Injunction Over HCV Immunoassays
1 August 1994
Dual Cell Therapy Tested In Cancer
18 July 1994
SERONO/ORGANON PATENT DISPUTE
27 June 1994
MORE QUESTIONS THAN ANSWERS IN EU POLICY
4 April 1994
ZEMURON LAUNCHED IN USA SOON
28 March 1994
THERIAK LICENSE CELL GENESYS' FSH
7 March 1994
ARES-SERONO WINS FSH PATENT DISPUTE
14 February 1994
FRAGMIN APPROVABLE, SAYS FDA
24 January 1994
ANAGEN PROFITS
25 October 1993
FDA REPORT ON ZEMURON
25 October 1993
PATENT SUITS OVER FERTILITY HORMONE
26 July 1993
ANAGEN SEEKING FLOTATION
3 May 1993
ARES-SERONO FILES NEW rFSH SUIT
26 April 1993
ARES-SERONO NETPROFITS LEAP 51%
15 March 1993
SANKYO LAUNCHES NEW PRODUCTS
8 March 1993
UNITED BIOMEDICAL PRODUCT UPDATE
22 February 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
ORGANON ACQUIRES GERMAN FIRM
25 January 1993
BIOCHEM PHARMA ITALIAN DEAL
18 January 1993
JOHNSON & JOHNSON RECEIVES APPROVAL
21 December 1992
NEURO AGENTS AND PARALYSIS
21 December 1992
SHIFTS FORECAST IN US CONTRACEPTIVES MARKET
3 August 1992
Chiron/Ortho infunction fails
22 June 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
